Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor (APTBCy) is a PHASE2 clinical asset sponsored by St. Petersburg State Pavlov Medical University in Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia, Myelodysplastic Syndromes (MDS), Myeloprolipherative Neoplsm, Atypical Chronic Myeloid Leukemia. SEO and diligence focus: Ruxolitinib, Abatacept (Orencia), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.